Stock listing
OTC:BRGX BioRegenx, Inc Stock
Follow BioRegenx, Inc into a list and get an email when it puts out news.
Share price · OTC:BRGX
$0.0002 USD 0.0000 (0.0%)
Close on Oct 30, 2026
- Day range
- $0.0002 – $0.0002 USDOct 30, 2026
- Market cap
- $194,315 USDAt the close on Oct 30, 2026 · price × 971.6M shares outstanding
- 52-week range
- $0.0002 – $0.0240 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $263 USDMedian day 0 shares · 37 days with no trades · last 3 months, Jul 30, 2026 – Oct 30, 2026

Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · OTC:BRGX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 12,500 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 300,000 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0005 | $0.0002 | 17,600 | |
| $0.0002 | -0.0038 | -95.0% | $0.0002 | $0.0002 | $0.0002 | 5,000 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0040 | 0 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0040 | 0 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0040 | 0 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0040 | 0 | |
| $0.0040 | -0.0010 | -20.0% | $0.0040 | $0.0040 | $0.0040 | 74,222 | |
| $0.0050 | +0.0020 | +66.7% | $0.0030 | $0.0050 | $0.0030 | 351,164 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 0 | |
| $0.0030 | -0.0015 | -33.3% | $0.0030 | $0.0030 | $0.0030 | 70,765 | |
| $0.0045 | +0.0015 | +50.0% | $0.0050 | $0.0050 | $0.0045 | 800,000 | |
| $0.0030 | -0.0058 | -65.9% | $0.0040 | $0.0040 | $0.0030 | 17,500 | |
| $0.0088 | +0.0043 | +95.6% | $0.0088 | $0.0088 | $0.0088 | 60,213 | |
| $0.0045 | +0.0005 | +12.5% | $0.0040 | $0.0045 | $0.0040 | 41,755 | |
| $0.0040 | +0.0005 | +14.3% | $0.0040 | $0.0040 | $0.0037 | 180,000 | |
| $0.0035 | -0.0005 | -12.5% | $0.0030 | $0.0035 | $0.0030 | 141,878 | |
| $0.0040 | -0.0015 | -27.3% | $0.0050 | $0.0052 | $0.0030 | 198,000 | |
| $0.0055 | 0.0000 | 0.0% | $0.0055 | $0.0055 | $0.0055 | 0 | |
| $0.0055 | 0.0000 | 0.0% | $0.0055 | $0.0055 | $0.0055 | 0 | |
| $0.0055 | 0.0000 | 0.0% | $0.0055 | $0.0055 | $0.0055 | 0 | |
| $0.0055 | -0.0010 | -15.4% | $0.0055 | $0.0055 | $0.0055 | 225 | |
| $0.0065 | 0.0000 | 0.0% | $0.0065 | $0.0065 | $0.0065 | 0 | |
| $0.0065 | 0.0000 | 0.0% | $0.0065 | $0.0065 | $0.0065 | 0 | |
| $0.0065 | 0.0000 | 0.0% | $0.0065 | $0.0065 | $0.0065 | 0 | |
| $0.0065 | +0.0005 | +8.3% | $0.0060 | $0.0065 | $0.0060 | 75,000 | |
| $0.0060 | -0.0010 | -14.3% | $0.0060 | $0.0060 | $0.0060 | 75,002 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0070 | 0 | |
| $0.0070 | +0.0025 | +55.6% | $0.0070 | $0.0070 | $0.0070 | 100 | |
| $0.0045 | 0.0000 | 0.0% | $0.0045 | $0.0045 | $0.0045 | 100,000 | |
| $0.0045 | -0.0007 | -13.5% | $0.0056 | $0.0056 | $0.0030 | 394,555 | |
| $0.0052 | 0.0000 | 0.0% | $0.0052 | $0.0052 | $0.0052 | 0 | |
| $0.0052 | 0.0000 | 0.0% | $0.0052 | $0.0052 | $0.0052 | 0 | |
| $0.0052 | 0.0000 | 0.0% | $0.0052 | $0.0052 | $0.0052 | 0 | |
| $0.0052 | -0.0003 | -5.5% | $0.0055 | $0.0055 | $0.0025 | 138,188 | |
| $0.0055 | -0.0025 | -31.3% | $0.0051 | $0.0055 | $0.0050 | 355,500 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0080 | 0 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0080 | 0 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0080 | 0 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0080 | 0 | |
| $0.0080 | 0.0000 | 0.0% | $0.0065 | $0.0080 | $0.0063 | 90,000 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0080 | 0 | |
| $0.0080 | +0.0015 | +23.1% | $0.0080 | $0.0080 | $0.0075 | 227,390 | |
| $0.0065 | +0.0005 | +8.3% | $0.0065 | $0.0065 | $0.0065 | 2,000 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 0 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 0 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 0 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 0 | |
| $0.0060 | 0.0000 | 0.0% | $0.0060 | $0.0060 | $0.0060 | 0 | |
| $0.0060 | +0.0005 | +9.1% | $0.0060 | $0.0060 | $0.0060 | 6,578 | |
| $0.0055 | -0.0005 | -8.3% | $0.0055 | $0.0055 | $0.0055 | 10,000 | |
| $0.0060 | -0.0010 | -14.3% | $0.0069 | $0.0069 | $0.0060 | 15,002 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0070 | 0 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0070 | 0 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0070 | 0 | |
| $0.0070 | -0.0005 | -6.7% | $0.0060 | $0.0070 | $0.0060 | 7,750 | |
| $0.0075 | 0.0000 | 0.0% | $0.0075 | $0.0075 | $0.0075 | 0 | |
| $0.0075 | 0.0000 | 0.0% | $0.0075 | $0.0075 | $0.0075 | 0 | |
| $0.0075 | 0.0000 | 0.0% | $0.0075 | $0.0075 | $0.0075 | 0 | |
| $0.0075 | 0.0000 | 0.0% | $0.0075 | $0.0075 | $0.0075 | 0 | |
| $0.0075 | 0.0000 | 0.0% | $0.0075 | $0.0075 | $0.0075 | 0 | |
| $0.0075 | 0.0000 | 0.0% | $0.0075 | $0.0075 | $0.0075 | 0 |
Splits
6 splits since 2002 · OTC:BRGX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-100 | Consolidation | |
| 3-for-1 | Split | |
| 1-for-15 | Consolidation | |
| 1-for-5 | Consolidation | |
| 1-for-3 | Consolidation |
- Ticker
- OTC:BRGX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news
BioRegenx, Inc on 6ix
- News releases
- 1 in the last 12 months · 197 in all · newest Dec 9, 2025 · oldest 2019
Valuation
Statements: 4 quarters to Mar 31, 2026 · price Oct 30, 2026
- Enterprise value
- $2.31M USD
- P/E
- Loss
- EV/sales
- 1.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 81.9%
- Operating margin
- −62.4%
- Net margin
- −73.8%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -0.20
Team and board
Officers
| Officer | Role |
|---|---|
| Diane Bouis | Acting CEO MVHS |
| William Resides | CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD, BIOREGENX AND NULIFE SCIENCES & DIRECTOR |
| Richard Janney | Strategic CFO & Board Member |
| Gary Hennerberg | Secretary |
Board
| Director | Role |
|---|---|
| William Resides | CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD, BIOREGENX AND NULIFE SCIENCES & DIRECTOR |
| Richard Janney | Strategic CFO & Board Member |
| Suzanne Bird | Director |
| Thomas Powers | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Nov 14, 2025 | −54.2% |
| Q2 2025 | Aug 14, 2025 | −23.5% |
| Q1 2025 | May 21, 2025 · After close | −25.9% |
| Q3 2024 | Nov 18, 2024 · After close | +4.0% |
| Q1 2024 | May 23, 2024 · After close | +40.7% |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.85M | 2.34M | 3.41M | 42.2K | 198.6K | 404.4K | 478.1K | 257.9K | 268.5K | 343.7K |
| Cost of revenue | 350.9K | 681.7K | 1.10M | 0 | 554 | 45.0K | 213.1K | 1.41K | ||
| Gross profit | 1.50M | 1.66M | 2.31M | 42.2K | 198.0K | 359.4K | 265.0K | 256.5K | ||
| Research and development | 31.8K | 0 | 257.7K | 1.18M | 317.6K | |||||
| Selling, general and administrative | 2.01M | 5.85M | 5.23M | 55.6K | 147.7K | 132.6K | 467.1K | 290.7K | ||
| Operating income | -1.24M | -22.8M | -3.41M | -78.3K | -165.1K | -216.0K | -210.0K | -47.3K | -74.1K | 12.0K |
| Depreciation and amortization | 75.1K | 2.22M | 4.77K | 5.93K | 4.45K | 5.93K | 5.93K | 5.93K | ||
| EBITDA | -1.17M | -20.5M | -3.40M | -72.4K | -160.7K | -210.1K | -204.1K | -41.4K | ||
| Interest expense | 299.6K | 290.7K | 292.2K | 0 | 7.28K | 2.57K | ||||
| Income before tax | -1.54M | -23.1M | -1.28M | -78.3K | -96.9K | -274.0K | -208.0K | -47.3K | -81.4K | 9.42K |
| Income tax | 0 | 0 | 0 | 58.1K | ||||||
| Net income | -1.54M | -23.1M | -3.60M | -78.3K | -96.9K | -332.0K | -208.0K | -47.3K | -81.4K | 9.42K |
| Earnings per share, basic | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | 0.00 | |
| Earnings per share, diluted | 0.00 | -0.03 | -0.01 | 0.00 | 0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 69.4K | 58.4K | 125.4K | 676 | 24.4K | 93.9K | 38.0K | 3.13K | 6.58K | |
| Receivables | 39.7K | 15.0K | 104.6K | 985 | 971 | |||||
| Inventory | 106.9K | 111.1K | 217.5K | 653.3K | 850.3K | |||||
| Current assets | 251.3K | 307.8K | 652.7K | 676 | 24.4K | 94.8K | 38.0K | 3.01K | 6.58K | |
| Property, plant and equipment | 159.7K | 200.7K | 13.7K | |||||||
| Goodwill | 0 | |||||||||
| Total assets | 411.0K | 508.5K | 865.8K | 59.1K | 127.8K | 367.7K | 91.8K | 61.6K | 101.8K | |
| Accounts payable | 616.0K | 427.5K | 241.7K | 19.7K | 12.0K | 33.1K | 71.0K | 12.9K | 38.1K | |
| Current liabilities | 4.07M | 3.63M | 2.79M | 64.9K | 14.2K | 41.5K | 77.5K | 75.6K | 73.0K | |
| Long-term debt | 181.8K | 254.6K | 0 | 195.8K | 197.8K | 148.5K | ||||
| Total debt | 1.19M | 1.14M | 200.0K | 200.0K | 200.0K | 150.0K | ||||
| Total liabilities | 4.95M | 3.89M | 2.94M | 260.7K | 212.0K | 190.1K | 77.5K | 75.6K | 73.0K | |
| Shareholders' equity | -4.54M | -3.38M | -2.07M | -2.53M | -84.2K | 177.6K | 14.2K | 45.5K | 28.8K | |
| Shares outstanding | 969.0M | 957.0M | 770.8M | 269.7M | 956.6M | 268.0M | 265.7M | 1.60B | 1.60B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 39.0K | -324.1K | -1.52M | -64.7K | -119.5K | -94.1K | -142.3K | -56.7K |
| Capital spending | -9.06K | -189.4K | 0 | 0 | -31.5K | 0 | 0 | 0 |
| Free cash flow | 29.9K | -513.5K | -1.52M | -64.7K | -151.1K | -94.1K | -142.3K | -56.7K |
| Cash from investing | -59.1K | -187.9K | -199.4K | 0 | 0 | |||
| Cash from financing | 33.1K | 442.1K | 1.20M | 41.0K | 50.0K | 150.0K | 177.2K | 58.8K |
| Change in cash | 11.0K | -67.0K | -491.3K | -23.7K | -69.5K | 55.9K | 34.8K | 3.01K |
Cap table
Built by 6ix from BioRegenx, Inc’s releases
- Common shares
- 971,575,183
- Fully diluted
- 971,575,183
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 971,575,183 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 971,575,183 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard Janney Other companies: Skye Bioscience, Inc. (Principal Accounting Officer · Sep 25, 2020 – Sep 25, 2020 · Past); Asyst Technologies Inc (Interim CFO and interim PAO · Sep 25, 2006 – Sep 25, 2006 · Past) | Strategic CFO & Board Member · Since at least Oct 7, 2024 |
| Diane Bouis | Acting CEO MVHS · Since at least Nov 4, 2026 |
| Gary Hennerberg | Secretary · Since at least Mar 8, 2024 |
| Gary Kiss | Director · Mar 8, 2024 – Mar 8, 2024 · Past |
| Jody Marie Walker | Director · Mar 8, 2024 – Mar 8, 2024 · Past |
| Robert Doran | Executive Vice President, Director · Mar 8, 2024 – Mar 8, 2024 · Past |
| Sherri Adams | Chief Operating Officer, Director · Mar 8, 2024 – Mar 8, 2024 · Past |
| Suzanne Bird | Director · Since at least Mar 8, 2024 |
| Thomas Powers | Director · Since at least Nov 5, 2026 |
| William Resides | CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD, BIOREGENX AND NULIFE SCIENCES & DIRECTOR · Since at least Mar 8, 2024 |
Log in to ask 6ix AI your own questions about BioRegenx, Inc.